v3.26.1
Segment and Geographic Data
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
We segregate our operations into two reportable business
segments: (i) MedSurg and Neurotechnology and (ii)
Orthopaedics which aligns to our internal reporting structure and
how our Chief Operating Decision Maker (CODM) assesses the
performance and allocates resources. The CODM is the Chief
Executive Officer. The CODM makes decisions on resource
allocation, assesses performance of the business, and monitors
budget versus actual results using segment operating income.
Information about total assets by segment is not disclosed
because such information is not regularly provided to, or used by,
our CODM.
Segment Results
Three Months
2026
2025
MedSurg and Neurotechnology
$3,207
$3,056
Orthopaedics
2,813
2,810
Net sales
$6,020
$5,866
MedSurg and Neurotechnology
$1,291
$1,175
Orthopaedics
823
775
Cost of sales
$2,114
$1,950
MedSurg and Neurotechnology
$231
$208
Orthopaedics
146
158
Segment research, development and
engineering expenses
$377
$366
MedSurg and Neurotechnology
$930
$859
Orthopaedics
880
925
Segment selling, general and
administrative expenses
$1,810
$1,784
MedSurg and Neurotechnology
$55
$48
Orthopaedics
119
107
Segment depreciation and amortization
$174
$155
Corporate and Other
$43
$39
Amortization of intangible assets
180
167
Total depreciation and amortization
$397
$361
MedSurg and Neurotechnology
$700
$757
Orthopaedics
846
854
Segment operating income
$1,546
$1,611
Items not allocated to segments:
Corporate and Other
$(275)
$(267)
Inventory stepped up to fair value
—
(34)
Acquisition and integration-related charges
(19)
(185)
Amortization of intangible assets
(180)
(167)
Structural optimization and other special
charges
(118)
(41)
Goodwill and other impairments
—
(35)
Medical device regulation
(5)
(12)
Recall-related matters
(10)
(33)
Regulatory and legal matters
(3)
—
Consolidated operating income
$936
$837